Randomized Phase II Study of Pemetrexed Versus Gefitinib in Previously Treated Patients with Advanced Non-small Cell Lung Cancer

다국어 초록 (Multilingual Abstract)

Purpose This study aimed to evaluate the efficacy and safety of pemetrexed versus gefitinib in patients with advanced non-small cell lung cancer (NSCLC) previously treated with chemotherapy.

Materials and Methods Patients with advanced (stage IIIB or IV) or recurrent NSCLC were randomly assigned to receive either 500 mg/m! of pemetrexed intravenously every 3 weeks or gefitinib 250 mg/day orally. The primary end point was progression-free survival (PFS) at 6 months.

Results A total of 95 patients were enrolled (47 for pemetrexed and 48 for gefitinib). Most patients were male (72%) and current/ex-smokers (69%), and 80% had non-squamous cell carci- noma. The epidermal growth factor receptor (EGFR) mutation status was determined in 38 patients (40%); one patient per each arm was positive for EGFR mutation. The 6-month PFS rates were 22% and 15% for pemetrexed and gefitinib, respectively (p=0.35). Both arms showed an identical median PFS of 2.0 months and a median overall survival (OS) of 8.5 months. In EGFR wild-type patients, higher response rate (RR) and longer PFS as well as OS were achieved via pemetrexed compared with gefitinib, although there were no signifi- cant differences (RR: 39% vs. 9%, p=0.07; median PFS: 6.6 months vs. 3.1 months, p=0.45; median OS: 29.6 months vs. 12.9 months, p=0.62). Toxicities were mild in both treatment arms. Frequently reported toxicities were anemia and fatigue for pemetrexed, and skin rash and anorexia for gefitinib.

Conclusion Both pemetrexed and gefitinib had similar efficacy with good tolerability as second-line treat- ment in unselected patients with advanced NSCLC. However, pemetrexed is considered more effective than gefitinib for EGFR wild-type patients.

참고문헌 (Reference)

1 Scagliotti G, "The differential efficacy of pemetrexed according to NSCLC histology : a review of two phase III studies" 14 : 253-263, 2009

2 Hanna N, "Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy" 22 : 1589-1597, 2004

3 Kawaguchi T, "Randomized phase III trial of erlotinib versus docetaxel as second-or third-line therapy in patients with advanced non-small-cell lung cancer : Docetaxel and Erlotinib Lung Cancer Trial(DELTA)" 32 : 1902-1908, 2014

4 Fossella FV, "Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinumcontaining chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group" 18 : 2354-2362, 2000

5 Shepherd FA, "Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy" 18 : 2095-2103, 2000

6 Maruyama R, "Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer" 26 : 4244-4252, 2008

7 Scagliotti GV, "Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapynaive patients with advanced-stage non-small-cell lung cancer" 26 : 3543-3551, 2008

8 Karampeazis A, "Pemetrexed versus erlotinib in pretreated patients with advanced non-small cell lung cancer : a Hellenic Oncology Research Group(HORG)randomized phase 3 study" 119 : 2754-2764, 2013

9 Paz-Ares LG, "PARAMOUNT : final overall survival results of thephase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer" 31 : 2895-2902, 2013

10 Douillard JY, "Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer : data from the randomized phase III INTEREST trial" 28 : 744-752, 2010

11 Ciuleanu T, "Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-smallcell lung cancer : a randomised, double-blind, phase 3 study" 374 : 1432-1440, 2009

12 Lee CK, "Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival : a meta-analysis" 105 : 595-605, 2013

13 Sun JM, "Gefitinib versus pemetrexed as second-line treatment in patients with nonsmall cell lung cancer previously treated with platinum-based chemotherapy (KCSG-LU08-01): an open-label, phase 3 trial" 118 : 6234-6242, 2012

14 Kim ES, "Gefitinib versus docetaxel in previously treated non-smallcell lung cancer(INTEREST) : a randomised phase III trial" 372 : 1809-1818, 2008

15 Thatcher N, "Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer : results from a randomised, placebo-controlled, multicentre study(Iressa Survival Evaluation in Lung Cancer)" 366 : 1527-1537, 2005

16 Garassino MC, "Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours(TAILOR) : a randomised controlled trial" 14 : 981-988, 2013

17 Ciuleanu T, "Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis(TITAN) : a randomised multicentre, open-label, phase 3 study" 13 : 300-308, 2012

18 Govindan R, "Changing epidemiology of small-cell lung cancer in the United States over the last 30 years : analysis of the surveillance, epidemiologic, and end results database" 24 : 4539-4544, 2006

19 Siegel R, "Cancer statistics, 2013" 63 : 11-30, 2013

20 정규원, "Cancer Statistics in Korea: Incidence, Mortality, Survival and Prevalence in 2010" 대한암학회 45 (45): 1-14, 2013

21 Azzoli CG, "American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-smallcell lung cancer" 27 : 6251-6266, 2009

22 Yang J, "A phase II trial comparing pemetrexed with gefitinib as the second-line treatment of nonsquamous NSCLC patients with wild-type EGFR (CTONG0806)" American Society of Clinical Oncology 2013

23 Azzoli CG, "2011 Focused update of 2009 American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-celllung cancer" 29 : 3825-3831, 2011